Ekso Bionics Holdings, Inc. Issues Amended 2025 Annual Report: Key Highlights for Investors

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has released Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment, filed on April 10, 2026, provides significant disclosures relevant to investors, including updates on governance, executive compensation, ownership, and recent corporate changes. Below, we provide a detailed breakdown of the most important and potentially price-sensitive items for shareholders.

Key Report Highlights

• Purpose of the Amendment: The amendment supplies the information required in Part III of the original 10-K, which was not included as the company’s definitive proxy statement was not filed within 120 days of fiscal year-end. It includes updated certifications and outstanding share counts, but does not update any financial statements or reflect events after the original filing date.
• Outstanding Shares Update: As of April 2, 2026, the company reports 3,563,381 shares of common stock outstanding. This is an important update for shareholders tracking dilution and ownership percentages.
• Corporate Structure & Listing: The company’s common stock continues to trade on the Nasdaq Stock Market LLC under the ticker symbol EKSO.

Corporate Governance and Compliance

• Filing Status: Ekso Bionics is a non-accelerated filer and a smaller reporting company. It is not an emerging growth company and not a well-known seasoned issuer.
• SEC Compliance: The company affirms it has filed all required reports under the Securities Exchange Act during the past 12 months, and all required Interactive Data Files have been submitted electronically.
• Internal Controls: The company’s auditor has not provided attestation on management’s assessment of internal controls over financial reporting, which is typical for smaller reporting companies.
• Section 16(a) Compliance: All directors, executive officers, and 10% shareholders complied timely with beneficial ownership filing requirements in 2025.
• Insider and Hedging Policies: Ekso Bionics maintains strict policies prohibiting hedging transactions and has an insider trading policy, both available for investor review. No directors or officers have adopted Rule 10b5-1 sales plans to automate stock transactions.

Executive Compensation

Summary of 2025 Executive Compensation:

• Compensation Structure: Compensation consists of base salary, bonuses, stock and option awards, and non-equity incentive plan compensation. The grant date fair value of equity awards is calculated per FASB ASC Topic 718.
• Performance Metrics: 2025 bonuses and incentives were tied to revenue, cash spend, and strategic milestones such as developing predictable revenue models, improving brand awareness, regulatory certifications, and product launches. The Compensation Committee exercised discretion in adjusting awards based on company and individual performance.

Ownership and Major Shareholders

• Major Holders: Cedar Holdings Management LLC owns 210,000 shares, representing 5.9% of the company’s common stock. No other holder is disclosed above 5%.
• Directors & Officers: Collectively, company directors and executives own less than 1% of shares outstanding.

Corporate Governance Structure

• Board Committees: The company maintains an Audit Committee, Compensation Committee, and Nominating & Corporate Governance Committee. Key responsibilities include audit oversight, executive compensation, risk management (including cybersecurity), and board nominations.
• No Related Party Transactions: No material related party transactions are disclosed for the year.
• No Legal Proceedings: No directors or associates are involved in material proceedings adverse to the company.
• No Family Relationships: There are no family relationships among directors or executive officers.

Equity Plans and Dilution

• Equity Incentive Plans: As of year-end, there were 818,050 shares subject to outstanding options/warrants with a weighted average exercise price of \$15.83. Only 224 shares remain available for future issuance under equity plans, a potential constraint on future equity-based compensation unless the plan is amended.

Exhibits and Key Documents

• Insider Trading Policy, Equity Plans, and Registration Rights: The report includes or references the company’s insider trading policy, equity incentive plans, key employment offer letters, and registration rights agreements. These can be found via the SEC’s EDGAR system.
• Updated Certifications: This amendment includes new CEO and CFO certifications under Section 302 of Sarbanes-Oxley.

Potentially Price-Sensitive Information

• Outstanding Shares Update: The updated share count may impact valuation metrics and is important for dilution calculations.
• Limited Equity Plan Shares Remaining: With only 224 shares available for future issuance under equity plans, the company may need to seek shareholder approval to increase the plan’s share pool, which can be a price-moving event.
• No Restatements or Error Corrections: The company explicitly states that there are no corrections to previously issued financials, nor any restatements requiring compensation clawbacks.
• Governance and Compliance: The absence of insider trading violations, related party transactions, or adverse legal proceedings is a positive for investors.

Conclusion for Investors

This amendment to Ekso Bionics Holdings’ 2025 Annual Report primarily delivers required Part III disclosures, a refreshed share count, and updated certifications. While there are no negative surprises or restatements, investors should note the low number of shares remaining for future equity compensation and monitor for any future proposals to expand this pool. The company continues to follow strong governance and compliance practices, with no material legal or related party issues reported.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings and consult with a financial advisor before making any investment decisions. The information above is based on the company’s 2025 10-K/A amendment and may not reflect subsequent events or filings.

View EKSO BIONICS HOLDINGS, INC. Historical chart here